Longevity Medicine
What Is Liquid Biopsy?
Last reviewed: May 2026 · Haute MD Editorial Team
Liquid biopsy is a blood-based test that detects cancer-derived material — most commonly circulating tumor DNA (ctDNA), but also circulating tumor cells and exosomes — released by tumors into the bloodstream. It is used both for early cancer detection and for monitoring known cancer, with rapidly expanding clinical applications.
How liquid biopsy works
Tumors continuously shed small fragments of DNA into the bloodstream as cells die or release vesicles. Modern sequencing can detect these fragments at very low frequencies (often below 0.1% of total cell-free DNA), distinguish them from normal cell-free DNA by mutation patterns or methylation signatures, and in many cases infer tissue of origin. Three major applications exist: (1) early detection (MCED tests like Galleri use methylation patterns to detect 50+ cancer types from a single tube of blood); (2) tumor profiling in patients with known cancer (replacing or supplementing tissue biopsy for treatment decisions); (3) minimal residual disease (MRD) monitoring after treatment, where ctDNA reappearance can detect recurrence months before imaging.
Where it fits in longevity practice
MCED liquid biopsies (Galleri being the most prominent) are increasingly offered in longevity and concierge practices to adults 50+ as an adjunct to standard screening. They have moderate sensitivity (~50% across all cancers, higher for advanced-stage and certain cancer types) but high specificity (~99%), and importantly can detect cancers for which no standard screening exists (pancreatic, ovarian, esophageal). Limitations include lower sensitivity for early-stage disease, false negatives, the cost of working up positive signals, and the absence of randomized mortality benefit data. In symptomatic or high-risk individuals, ctDNA-based tumor profiling and MRD monitoring are becoming standard-of-care in oncology and have clearer evidence.
How to think about liquid biopsy as a patient
(1) Liquid biopsy is an adjunct, not a replacement for guideline screening (colonoscopy, mammography, lung CT in smokers); (2) Understand sensitivity — a negative test does not rule out cancer, particularly early-stage; (3) Understand workup pathway — positive MCED results typically trigger PET/CT or whole-body MRI to localize the signal, with associated cost and incidental findings; (4) Discuss appropriateness with a physician familiar with the test characteristics — particularly relevant if you have family history, prior cancer, or germline mutations; (5) Repeat annually if pursued — single-time-point screening misses many cancers; (6) Expect rapid evolution — sensitivity, panel breadth, and cost are improving year over year, and randomized trials (NHS-Galleri among others) will clarify population benefit over the next several years.
Frequently Asked Questions
How accurate is the Galleri test?
In the PATHFINDER and other studies, overall sensitivity across 50+ cancer types is ~50%, increasing with stage (~17% stage I, ~40% stage II, ~77% stage III, ~90% stage IV). Specificity is ~99.5%. Cancer signal origin prediction is accurate in roughly 85% of true positives.
Does liquid biopsy replace mammography or colonoscopy?
No. It complements them. Many early-stage breast and colon cancers are detected by mammography and colonoscopy below liquid biopsy's detection threshold. The combination is more sensitive than either alone.
Is liquid biopsy covered by insurance?
MCED tests like Galleri are largely out-of-pocket (~$950) for screening. ctDNA testing in patients with known cancer is often covered. Coverage is likely to expand as evidence accumulates.
What happens if I get a positive MCED result?
Workup typically involves PET/CT or whole-body MRI guided by the predicted tissue of origin, plus targeted imaging or endoscopy. Most positive results lead to confirmed findings, but false positives do occur and the workup pathway should be discussed in advance.
Get Help Now
Speak with a Haute MD Longevity Medicine physician
Dr. George Kaltner
CEO
Longevity Medicine · Miami Beach, FL
View Profile
Dr. Alexander Golberg
Longevity Medicine · New York, NY
View Profile
Dr. Steven Victor
Regenerative Medicine Specialist
Longevity Medicine · New York, NY
View ProfileAre you a Longevity Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · LONGEVITY MEDICINE
What Is Multi-Cancer Early Detection?
Multi-cancer early detection (MCED) tests screen for dozens of cancers from a single blood sample using DNA methylation signatures.
Read GuideGuide · LONGEVITY MEDICINE
What Is Preventive Oncology?
Preventive oncology applies risk stratification, advanced screening, and lifestyle interventions to detect cancer earlier and reduce lifetime cancer risk.
Read GuideGuide · LONGEVITY MEDICINE
What Is Genetic Cancer Risk Testing?
Germline genetic testing identifies inherited cancer risk mutations like BRCA, Lynch, and others — enabling personalized prevention and screening.
Read Guide